Search
for
Sort by
Research
600-630 / 1000+ resultsresearch Comparative efficacy of topical anthralin and intralesional triamcinolone in the treatment of alopecia areata.
Triamcinolone regrows hair better but relapses more than anthralin.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research Candida antigen immunotherapy versus steroid in the treatment of alopecia areata
Candida antigen is an effective and promising treatment for alopecia areata.
research Asynchronous telemedicine for isotretinoin management: A direct care pilot
Asynchronous telemedicine for acne treatment is effective and improves access and productivity.
research Epidemiology of alopecia areata in Baqubah city/Diyala-Iraq
Alopecia areata is common in young males and linked to stress.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Hirsutism in Algeria: Etiologic study
The main cause of hirsutism in Algerian women is polycystic ovary syndrome, and those affected should be checked for related hormonal issues.
research Anti‐Doping Testing at FIFA World Cup 2022
All samples tested negative for banned substances, ensuring competition integrity.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research Kadınlarda Kronik İdyopatik Telogen Effluvium
The document's conclusion cannot be provided because the content is not in a processable format.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research ANALYSIS OF CTLA 4 GENE +49A/G AND CT60 A/G POLYMORPHISMS IN ALOPECIA AREATA PATIENTS
CT60 polymorphism might increase the risk of Alopecia Areata.
research A retrospective analysis of efficacy and safety of intralesional triamcinolone injections in the treatment of frontal fibrosing alopecia either as monotherapy or as a concomitant therapy
Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
research Platelet rich plasma intradermal injections the area of expression of CD34 and B-catenin in males with androgenetic alopecia 11th World Congress for Hair Reserch
research 2018 ISPAN Meeting Abstracts
The 2018 ISPAN Meeting emphasized hands-on learning, patient safety, and professional growth in medical aesthetics and reconstructive practices.
research 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Intralesional steroids for alopecia areata
Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID ‐19 pandemic
Searches for acne, hair loss, and eczema increased during COVID-19, while searches for other skin issues decreased.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.